FFA
ABUS icon

Farther Finance Advisors’s Arbutus Biopharma ABUS Stock Holding History

Farther Finance Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$650 Buy
+136
New +$655 ﹤0.01% 5689
2026
Q2 		– Sell
-117
Closed -$529 – 5976
2026
Q1 		$529 Hold
117
– – ﹤0.01% 5255
2025
Q4 		$563 Sell
117
-139
-54% -$625 ﹤0.01% 5032
2025
Q3 		$1.16K Buy
+256
New +$940 ﹤0.01% 4323
2025
Q2 		– Sell
-266
Closed -$926 – 4489
2025
Q1 		$926 Sell
266
-7,734
-97% -$25.8K ﹤0.01% 3633
2024
Q4 		$26.2K Hold
8,000
– – ﹤0.01% 1970
2024
Q3 		$30.8K Hold
8,000
– – ﹤0.01% 1887
2024
Q2 		$25K Hold
8,000
– – ﹤0.01% 1709
2024
Q1 		$20.5K Buy
+8,000
New +$20.7K ﹤0.01% 1485

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's ABUS Position: Q3 2026 in Review

Farther Finance Advisors opened a new position in Arbutus Biopharma (ABUS) in Q3 2026: 136 shares worth $650. The stake represents ﹤0.01% of the portfolio and ranks #5689 among its holdings. This is a return to the name: Farther Finance Advisors previously reported a position in ABUS as recently as Q1 2026.

Farther Finance Advisors first reported a position in ABUS in Q1 2024 and has held it in 9 quarters since. The position peaked at $30.8K in Q3 2024. 5 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Farther Finance Advisors held 136 shares of Arbutus Biopharma worth $650 as of Q3 2026.
  • Arbutus Biopharma was a new Farther Finance Advisors position in Q3 2026.
  • Arbutus Biopharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5689 holding.
  • Farther Finance Advisors first reported a position in Arbutus Biopharma in Q1 2024 and has held it in 9 quarters since.
  • Farther Finance Advisors's Arbutus Biopharma position peaked at $30.8K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.